^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TP53 overexpression

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
9d
AMPK/MTOR/TP53 Signaling Pathway Regulation by Calcitonin Gene-Related Peptide Reduces Oxygen-Induced Lung Damage in Neonatal Rats through Autophagy Promotion. (PubMed, Inflammation)
Furthermore, hyperoxia increased the expression levels of AMP-activated protein kinase (AMPK) alpha 1 (also known as protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1)) but inhibited TP53 and mechanistic target of rapamycin (MTOR); these expression trends were regulated by CGRP treatment. In conclusion, we showed that CGRP can attenuate hyperoxia-induced lung injury in neonatal rats by enhancing autophagy and regulating the TP53/AMPK/MTOR crosstalk axis.
Preclinical • Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
|
TP53 overexpression
|
sirolimus
9d
P53 Overexpression May Represent an Early Marker of Clinicopathologic Progression in Vasculogenic Mesenchymal Lesions of Germ Cell Tumor Origin. (PubMed, Virchows Arch)
P53 overexpression is associated with disease progression in a subset of VMTs and may precede morphologic transformation to sarcoma. Routine evaluation of VMTs with p53 IHC seems justified, with overexpressors likely requiring an close clinical surveillance.
Journal
|
TP53 (Tumor protein P53)
|
TP53 overexpression
9d
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=11, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
23d
Comparative Expression Analysis of TP53 Tumor Suppressor and MDM2 Oncogene in Colorectal Adenocarcinoma. (PubMed, Cancer Diagn Progn)
TP53/MDM2 over expression is a frequent and significant genetic event in CRCs associated with an aggressive biological behavior, as a result of increased dedifferentiation grade and advanced stage/elevated tumor volume, respectively. MDM2 oncogene overactivation combined with mutated and overexpressed TP53 is observed in sub-groups of patients leading to specific gene/protein signatures - targets for personalized chemotherapeutic approaches.
Journal
|
TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
|
TP53 mutation • TP53 expression • TP53 overexpression • MDM2 overexpression
2ms
Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies. (PubMed, Pathology)
Performance in our setting differs from the literature, which shows variability of pre-analytic factors and cut-offs used to screen for TP53 mutations. Each laboratory should validate p53 IHC to screen for TP53 mutations in their unique setting.
Journal • Biopsy
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 overexpression
2ms
A New Benzo[6,7]oxepino[3,2-b] Pyridine Derivative Induces Apoptosis in Canine Mammary Cancer Cell Lines. (PubMed, Animals (Basel))
In conclusion, the results of the present study suggested that MPOBA exhibited significant anticancer activity by inducing apoptosis in both CMCs via upregulation of TP53 and BAX and downregulation of BCL-2 relative mRNA expression. MPOBA may prove to be a potential candidate drug to be further investigated as a therapeutic agent for CMC.
Preclinical • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2) • ANXA5 (Annexin A5)
|
EGFR expression • TP53 overexpression • BAX expression • VIM expression
3ms
High-grade Solid Pseudopapillary Neoplasms of the Pancreas: Distinct Clinicopathological Malignant Features With Intriguing Gene Alterations through a Comparison With the Conventional Type. (PubMed, Am J Surg Pathol)
Two HG-SPN cases had TP53 mutation and/or p53 overexpression. In conclusion, HG-SPNs show distinct malignant features and some genetic alterations that differ from C-SPNs, indicating the importance of differentiating between these 2 subtypes.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • NCAM1 (Neural cell adhesion molecule 1) • VIM (Vimentin) • MME (Membrane Metalloendopeptidase)
|
TP53 mutation • RB1 mutation • CTNNB1 mutation • TP53 overexpression • VIM expression
3ms
Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. (PubMed, Cancer Med)
Isolated TP53 mutation was seen in association with smoking, high-grade cytomorphologic features, adverse prognosis, and recurrent CEBPA deletions. These tumors tend to have strong PD-L1 expression and high TMB, suggesting potential benefit from immune checkpoint inhibitors. Hence, the recognition of this molecular group has prognostic and therapeutic implications.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • NKX2-1 (NK2 Homeobox 1)
|
TP53 mutation • TMB-H • PD-L1 overexpression • CEBPA mutation • TP53 overexpression • TP53 mutation + TMB-H + PD-L1 overexpression
3ms
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
3ms
P53 expression correlates with low axillary tumor burden in breast cancer. (PubMed, Breast Dis)
p53+ breast cancers were associated with worse overall survival. However, low ATB was more common in these tumors than in p53- tumors in the luminal B-Her2-negative subtype. Information on p53 expression could be of use to predict ATB in some breast cancer tumors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53)
|
TP53 mutation • HER-2 negative • TP53 expression • TP53 overexpression
3ms
Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study. (PubMed, Blood Adv)
Ibrutinib +/- rituximab was effective and well tolerated as first-line treatment of MCL, including older and transplant-ineligible patients. PFS and OS were significantly inferior in one-third of patients with high-risk disease and those unsuitable for post-ibrutinib treatment, highlighting the need for novel approaches in these groups.
Journal • Real-world evidence • Real-world
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 overexpression
|
Imbruvica (ibrutinib) • Rituxan (rituximab)
4ms
Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis. (PubMed, Sci Rep)
CCDC106 overexpression downregulates the cellular level of p53 and Mdm2/MdmX, and decreased p53 reversibly downregulates the cellular level of CCDC106. Our work provides a molecular mechanism by which CCDC106 regulates the cellular levels of p53 and Mdm2/MdmX.
Journal
|
MDM2 (E3 ubiquitin protein ligase)
|
TP53 overexpression • MDM2 overexpression
4ms
Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration (ASH 2023)
This study revealed that high expression of MMR proteins is a common feature of DLBCL associated with lower tumor-infiltrating T cells, MYC and p53 overexpression, and context-dependent prognostic effects. In contrast, dMMR and loss of MMR proteins are infrequent and have no significant prognostic effects in DLBCL treated with standard chemoimmunotherapy. These results may have implications for understanding DLBCL biology and the low efficacy of PD-1 blockade immunotherapy in DLBCL.
Mismatch repair • PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
MSI-H/dMMR • MYC overexpression • MYC expression • MSH6 mutation • MLH1 mutation • PMS2 mutation • TP53 overexpression • MSH6 expression
4ms
IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia. (PubMed, Histopathology)
IDH1-mutated CrD-SBAs, which represent approximately one-fifth of total cases, are characterised by distinctive immunophenotypical features and methylation profiles, with potential therapeutic implications. Moreover, IDH1-mutated non-conventional, serrated dysplasia is likely to represent a precursor lesion to such CrD-SBAs.
Journal
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH1 mutation • IDH1 R132C • TP53 overexpression • IDH wild-type • IDH1 R132
4ms
Mutant p53 gain-of-function stimulates canonical Wnt signaling via PI3K/AKT pathway in colon cancer. (PubMed, J Cell Commun Signal)
We also found that while wt-p53 expression contributes to 5-FU sensitivity in colon cancer cells, the RITA p53 reactivating molecule counteracted the resistance against 5-FU in cells expressing mut-p53. Our results indicate that mut-p53 GOF acts as a positive regulator of canonical Wnt signaling and participates in the induction of resistance to 5-FU in colon cancer cells.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type • TP53 overexpression
|
5-fluorouracil • RITA
4ms
Mutant p53 ameliorates inflammatory arthritis in AIA rats via inhibition of TBK1-IRF3 innate immune response. (PubMed, Inflamm Res)
This study unravels the role of p53 mutant in RA pathogenesis, and identifies TBK1 as a potential anti-inflammatory target.
Preclinical • Journal
|
TP53 (Tumor protein P53) • STING (stimulator of interferon response cGAMP interactor 1)
|
TP53 mutation • TP53 wild-type • TP53 overexpression
|
methotrexate
4ms
Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy. (PubMed, Future Med Chem)
Therefore, mortalin-p53 sequestration inhibitors could be game changers in improving overall survival rates. This review explores the consequences of mortalin overexpression and challenges, status and strategies for accelerating drug discovery to suppress mortalin-p53 sequestration.
Review • Journal
|
HSPA9 (Heat Shock Protein Family A (Hsp70) Member )
|
TP53 mutation • TP53 wild-type • TP53 overexpression
4ms
The Spectrum of HPV-independent Penile Intraepithelial Neoplasia: A Proposal for Subclassification. (PubMed, Am J Surg Pathol)
Four histologically different HPV-independent penile precursor lesions can be assigned to 2 major genetic/biological pathways with characteristic highly differentiated precursors requiring different clinical management decisions. These include d-PeIN in chronic inflammatory dermatoses, with p53 overexpression and TP53/CDKN2A mutations, and the p53 wild-type verrucous and verruciform precursors unassociated with dermatoses, but with mutations in oncogenes PIK3CA and HRAS.
Journal
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
TP53 mutation • PIK3CA mutation • TP53 wild-type • CDKN2A mutation • HRAS mutation • CDKN2A negative • CDKN2A overexpression • TP53 overexpression
5ms
Apoptosis-Mediated Anticancer Activity of Ganoderma colossus (Agaricomycetes) Extracts in Breast Cancer Cells. (PubMed, Int J Med Mushrooms)
The GC- MS spectral data of the ethyl acetate crude extract of the mushroom indicated the presence of molecules capable of inducing apoptosis. The present study warrants further studies to isolate the molecule(s) from G. colossus which may be a potential drug candidate for breast cancers.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
TP53 overexpression
5ms
USP53 Exerts Tumor-Promoting Effects in Triple-Negative Breast Cancer by Deubiquitinating CRKL. (PubMed, Cancers (Basel))
Overall, we discovered that USP53 deubiquitinates CRKL, encourages tumor development and metastasis, and reduces chemosensitivity in TNBC. These findings imply that USP53 might represent a new therapeutic target for the treatment of TNBC.
Journal
|
CRKL (CRK Like Proto-Oncogene, Adaptor Protein)
|
TP53 overexpression
5ms
DNA2 nuclease inhibition confers synthetic lethality in cancers with mutant p53 and synergizes with PARP inhibitors. (PubMed, Cancer Res Commun)
Overexpression of DNA2 is associated with poor outcome in ovarian cancer. Overall, our results provide a rationale to target DNA2 as a new synthetic lethality approach in mutp53-bearing cancers, and further extend the benefit of PARP inhibitors beyond BRCA-mutated cancers.
Journal • BRCA Biomarker • PARP Biomarker • Synthetic lethality
|
TP53 (Tumor protein P53) • BRCA (Breast cancer early onset) • DNA2 (DNA Replication Helicase/Nuclease 2)
|
TP53 mutation • TP53 overexpression • BRCA mutation
6ms
Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysis. (PubMed, Histopathology)
Cytoplasmic p53 expression in patients with pulmonary NEC suggests a high TP53 mutation rate, which is associated with a poor prognosis similar to that in patients with p53 overexpression or complete absence. This cytoplasmic expression should not be misidentified as a wild-type expression. This is the first report, to our knowledge, that demonstrates the implication of cytoplasmic p53 expression in pulmonary NEC.
Journal • Next-generation sequencing
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type • TP53 expression • TP53 overexpression
6ms
Immunohistochemistry-Based Biomarkers and Impact on Outcomes Following Salvage Radiotherapy for Prostate Cancer. (PubMed, Int J Radiat Oncol Biol Phys)
PTEN loss identified by immunohistochemistry is an independent adverse prognostic factor for both biochemical and metastasis-free survival in prostate cancer patients treated with SRT. Although clinically validated RNA expression assays also exist which are prognostic for outcomes following SRT, stromal contamination in bulk RNA could mask "loss" signals specific to tumor cells, such as PTEN. Further work is necessary to determine the optimal approach to treating patients with poor molecular prognostic features in a salvage setting.
Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
|
TP53 mutation • PTEN deletion • TP53 overexpression
6ms
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). (PubMed, EClinicalMedicine)
The combination of ibrutinib and bortezomib shows durable efficacy in patients with relapsed or refractory MCL, also in the presence of high-risk features. SAKK (Hubacher Fund), Swiss State Secretariat for Education, Research and Innovation, Swiss Cancer Research Foundation, and Janssen.
P1/2 data • Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 overexpression
|
Imbruvica (ibrutinib) • bortezomib
7ms
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers. (PubMed, Front Immunol)
immunohistochemical assay is a reliable surrogate for TP53 mutations in most cases. Despite the small cohort and the limited median follow up, we can infer that HGSOC harboring p53 null mutations are a more aggressive subgroup.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 overexpression
7ms
Immunohistochemistry-Based Biomarkers and Impact on Outcomes Following Salvage Radiotherapy for Prostate Cancer (ASTRO 2023)
PTEN loss identified by immunohistochemistry is an independent adverse prognostic factor for both biochemical and metastasis-free survival in prostate cancer patients treated with SRT. Although clinically validated RNA expression assays also exist which are prognostic for outcomes following SRT, stromal contamination in bulk RNA could mask “loss” signals specific to tumor cells, such as PTEN. Further work is necessary to determine the optimal approach to treating patients with poor molecular prognostic features in a salvage setting.
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
|
TP53 mutation • PTEN deletion • TP53 overexpression
7ms
Clinicopathological features, cell cycle regulators and Ki 67 in dermatofibrosarcoma protuberans (ECP 2023)
Cyclin D1 and Ki67 may be associated with DFSP progression, and further, metastasis. p53 may be not involved in development of DFSP.
Clinical
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression • TP53 overexpression
7ms
Long noncoding RNA MIAT regulates TP53 ubiquitination and expedites prostate adenocarcinoma progression by recruiting TBL1X. (PubMed, Biochim Biophys Acta Mol Cell Res)
Silencing of TP53 or overexpression of TBL1X was enough to abate the tumor suppressive effects of MIAT knockdown in vitro and in vivo. Our results provide evidence for a novel regulation mechanism of CD8+ T cells in PRAD and MIAT may serve as a potential therapeutic target in PRAD.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • MIAT (Myocardial Infarction Associated Transcript)
|
TP53 overexpression
8ms
Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia (IWCLL 2023)
As far as the authors know here is presented the largest series which compares the phenotype between CLL and its DLBCL-RS. The markers CD19, CD20, CD5, CD79b, CD38, Ki67, and p53 showed relevant changes at the moment of histological transformation. This research enhances the importance of validating reproducible assays to follow hematological malignancies with potential of transformation to more aggressive diseases.
IO biomarker
|
TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAX (Integrin Subunit Alpha X) • SPN (Sialophorin) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CD20 expression • CD19 expression • TP53 overexpression • CD20 negative
8ms
Clinicopathologic and Molecular Characterization of Anorectal Neuroendocrine Carcinomas Reveals Human Papillomavirus, p53 and c-Myc as Alternative Mechanisms of Carcinogenesis. (PubMed, Mod Pathol)
Our study demonstrates that anorectal NECs arise in HPV-dependent or independent pathways, with heterogeneous expression of other lineage markers and different molecular signatures. Expression of p53 and c-Myc proteins appear to be mutually exclusive regardless of HPV status, likely mediating alternative mechanisms of NEC carcinogenesis.
Journal
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDX2 (Caudal Type Homeobox 2) • TP63 (Tumor protein 63)
|
MYC amplification • MYC expression • TP53 overexpression • CDX-2 overexpression
8ms
Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study. (PubMed, J Pers Med)
Even when treated with standard therapy, such as surgery followed by carboplatin and paclitaxel chemotherapy, the prognosis remains unfavorable. Patients with MSI had a lower CD8/PD-1 ratio and more relapses (p = 0.03). In conclusion, analysis of immunotherapeutic markers in paraffin-embedded advanced serous ovarian carcinoma samples is feasible and may assist in prognosis.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
PD-L1 expression • PD-1 expression • CD8 expression • TP53 overexpression • MSH6 expression
|
carboplatin • paclitaxel
8ms
Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma. (PubMed, Clin Lymphoma Myeloma Leuk)
p53 expression and CDKN2A deletion represent a reliable pretreatment prognostic factor that identifies patients who do not benefit from currently used immunochemotherapy-based therapies and who are candidates for diversified treatments with the aim of improving prognosis. The MIPIb represents a prognostic index that correlates well with these biological alterations and can be used in clinical practice as their surrogate.
Retrospective data • Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SOX11 (SRY-Box Transcription Factor 11)
|
CDKN2A deletion • CDKN2A overexpression • TP53 expression • TP53 overexpression
8ms
The Histologic and Molecular Spectrum of Highly Differentiated HPV-independent Cervical Intraepithelial Neoplasia. (PubMed, Am J Surg Pathol)
In conclusion, highly differentiated cervical HPV-negative precursors are characteristic intraepithelial squamous lesions with somatic mutations that resemble those described in vulvar HPV-independent carcinogenesis. For optimal reproducibility, we propose a simplistic classification of these HPV-negative cervical precursors in TP53-mutated d-CIN and p53 wild-type verruciform intraepithelial neoplasia.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
|
TP53 mutation • EGFR mutation • PIK3CA mutation • TP53 wild-type • CDKN2A negative • EGFR mutation + PIK3CA mutation • SMARCB1 mutation • TP53 overexpression
9ms
Expression of p53 as Potential Biomarker in Oral Submucous Fibrosis: An Immunohistochemical Study. (PubMed, J Microsc Ultrastruct)
The results indicate that p53 over expression may play a role in pathogenesis of OSMF and in the development of Oral squamous cell carcinoma. With early detection of the high-risk patients with OSMF, we can expect to develop more intensive treatment modalities, leading to the reduction in cancer transformation rate from OSMF.
Journal
|
TP53 (Tumor protein P53)
|
TP53 expression • TP53 overexpression
9ms
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) (clinicaltrials.gov)
P2, N=230, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 overexpression
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
9ms
Lost expression of AT-rich interaction domain 1A in the gastric mucosa-A constituent of field cancerization in the stomach. (PubMed, Pathol Int)
Mapping abnormal glands in the entire resected stomach of the three selected patients demonstrated that ARID1A-lost foci clustered with p53 abnormal glands. ARID1A-lost epithelial cells may develop clonal growth through the pathway, different from p53-abnormal intestinal metaplasia, and require one or more events to develop into an overt carcinoma, such as EBV infection.
Journal
|
ARID1A (AT-rich interaction domain 1A)
|
ARID1A mutation • TP53 overexpression
10ms
NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis. (PubMed, Int J Biol Markers)
NRF2, BIRC5, and TP53 axis gene expressions are predictors of poor prognosis for ESCC. The overexpression of the NRF2/HO-1/BIRC5 axis may not be related to immune-infiltrating cells.
Journal
|
TP53 (Tumor protein P53) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • BIRC5 (Baculoviral IAP repeat containing 5) • HMOX1 (Heme Oxygenase 1)
|
TP53 expression • TP53 overexpression • BIRC5 expression • BIRC5 overexpression • HMOX1 expression
10ms
α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis. (PubMed, Cell Death Discov)
In particular, TP53 overexpression derived from oxidative DNA damage, further leading to the activation of ferroptosis-related pathways. Our study demonstrated the importance of glutamine metabolism in DLBCL progression and highlighted the potential application of α-KG as a novel therapeutic strategy for DHL patients.
Journal
|
TP53 (Tumor protein P53)
|
TP53 overexpression
10ms
P53 and survivin expression in renal cell carcinoma. (PubMed, Urol Ann)
The results of this study suggest that p53 overexpression and survivin positivity in RCC patients could be associated with poor prognosis. Thus, these proteins could be used as prognostic markers in RCC.
Journal
|
TP53 (Tumor protein P53) • BIRC5 (Baculoviral IAP repeat containing 5)
|
TP53 mutation • TP53 overexpression • BIRC5 expression
10ms
Novel Monoclonal Antibodies Specific for Human Ki67 and P53 Tumor Markers in Breast Cancer Tissue Samples. (PubMed, Iran J Immunol)
Using these two monoclonal antibodies, we found a significant correlation between Ki67 and P53 overexpression and lymph node metastasis in patients with breast cancer. The present study showed that the novel anti-Ki67 and anti-P53 mAbs could recognize their respective antigens with high specificity and sensitivity and therefore can be used in prognostic studies.
Journal
|
TP53 (Tumor protein P53)
|
TP53 overexpression